The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Open accessAbstract
Background and Aims: We sought to analyze whether response to a second-line biologic varies depending on the reason for discontinuation of the primary anti-TNF agent (primary non-response [PNR], secondary loss of response [LOR] after initial response, or intolerance), through a systematic review and meta-analysis. Methods: Through a systematic search through May 31, 2017, we identified eight randomized controlled trials [RCTs] of biologics in patients with IBD with prior exposure to anti-TNF agents, that stratified response to second-line therapy by reason for discontinuing primary anti-TNF therapy [PNR vs. LOR vs. intolerance]. We estimated relative risk [RR] (and 95% confidence interval [CI]) of achieving clinical remission in patients with PNR as compared with patients with LOR, and intolerance, through random effects meta-analysis. Results: As compared with patients who discontinued prior anti-TNF due to intolerance, patients with prior PNR were 24% less likely to achieve remission with second-line biologics (RR,0.76 [0.61–0.96]). As compared with patients who discontinued prior anti-TNF due to LOR, patients with prior PNR were 27% less likely to achieve remission with induction therapy with second-line biologics (RR,0.73 [0.56–0.97]), particularly to ustekinumab (RR,0.64 [0.52–0.80]). There was no difference in response to vedolizumab in patients with prior PNR or LOR to anti-TNF agents (RR,1.16 [0.85–1.58]). Conclusion: Patients with PNR to anti-TNF agents are less likely to respond to second-line non-TNF biologics, as compared with patients who discontinued therapy due to secondary LOR or intolerance. This may be attributed to underlying pharmacokinetics and pharmacodynamics of anti-TNF agents in patients with PNR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Self-citation
Cited by
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Feuerstein, J. D., Isaacs, K. L., Schneider, Y., Siddique, S. M., Falck-Ytter, Y., Singh, S., Chachu, K., Day, L., Lebwohl, B., Muniraj, T., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.006 · Cited by 713
Self-citationFerrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00466-4 · Cited by 345
Self-citationUlcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Paradoxical gastrointestinal effects of interleukin-17 blockers
Fauny, M., Moulin, D., D'Amico, F., Netter, P., Petitpain, N., Arnone, D., Jouzeau, J.-Y., Loeuille, D., & Peyrin-Biroulet, L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217927 · Cited by 261
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Fanizza, J., D’Amico, F., Lauri, G., Martinez-Dominguez, S. J., Allocca, M., Furfaro, F., Zilli, A., Fiorino, G., Parigi, T. L., Radice, S., et al. (2024) · Immunotherapy · doi:10.2217/imt-2023-0116 · Cited by 16
Metadata
- Authors
- Singh, S., George, J., Boland, B. S., Vande Casteele, N., & Sandborn, W. J.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-23
- Volume
- 12
- Issue
- 6
- Pages
- 635-643
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2789693626
- Cited by
- 232
- References
- 3
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjy004
- The paper
- Singh, S., George, J., Boland, B. S., Vande Casteele, N., & Sandborn, W. J. (2018). Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjy004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.